FDA Inspection 1194802 — Incyte Corporation
The FDA completed an inspection of Incyte Corporation on November 18, 2022 in Wilmington, DE. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 18, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Wilmington, DE (United States)
Additional Details
Bioanalytical BA/BE